Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Autoimmune Disorders

Free Subscription Articles published in Brain Retrieve available abstracts of 140 articles: HTML format

Single Articles

July 2021
1. MITSDOERFFER M, Di Liberto G, Dotsch S, Sie C, et al
   Corrigendum to: Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity.
   Brain. 2021 Jul 14. pii: 6321151. doi: 10.1093.
   PubMed    
   
   
   June 2021
2. BITTNER S, Oh J, Havrdova EK, Tintore M, et al
   The potential of serum neurofilament as biomarker for multiple sclerosis.
   Brain. 2021 Jun 28. pii: 6310737. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. PELLERIN K, Rubino SJ, Burns JC, Smith BA, et al
   MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.
   Brain. 2021 Jun 18. pii: 6305830. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2021
4. GRANZIERA C, Wuerfel J, Barkhof F, Calabrese M, et al
   Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.
   Brain. 2021 May 10. pii: 6273092. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. VAN DOORN PA, Hadden RDM, Van den Bergh PYK
   Elucidating autoimmune nodopathies and the CIDP spectrum.
   Brain. 2021;144:1043-1045.
   PubMed    
   
   
   April 2021
6. FLECK AK, Hucke S, Teipel F, Eschborn M, et al
   Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity.
   Brain. 2021 Apr 26. pii: 6252379. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. GHORBANI S, Yong VW
   The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis.
   Brain. 2021 Apr 23. pii: 6247173. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. PARDINI M, Brown JWL, Magliozzi R, Reynolds R, et al
   Surface-in pathology in multiple sclerosis: a new view on pathogenesis?
   Brain. 2021 Apr 20. pii: 6238675. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. PISA M, Croese T, Dalla Costa G, Guerrieri S, et al
   Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes.
   Brain. 2021 Apr 8. pii: 6215108. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. LUCCHESE G, Floel A
    Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry.
    Brain. 2021 Apr 3. pii: 6209729. doi: 10.1093.
    PubMed    
    
    
    
11. LUNN MP, Carr AC, Keddie S, Pakpoor J, et al
    Reply: Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome and Unclear association between COVID-19 and Guillain-Barre syndrome and Currently avai
    Brain. 2021 Apr 3. pii: 6209732. doi: 10.1093.
    PubMed    
    
    
    
12. FOSCHI M, D'Anna L, Abdelhak A, Mayer B, et al
    Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209733. doi: 10.1093.
    PubMed    
    
    
    
13. GONZALEZ DEL CASTILLO J, Porta-Etessam J, Miro O
    Currently available data regarding the potential association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209731. doi: 10.1093.
    PubMed    
    
    
    March 2021
14. ONTANEDA D, Raza PC, Mahajan KR, Arnold DL, et al
    Deep grey matter injury in multiple sclerosis: A NAIMS consensus statement.
    Brain. 2021 Mar 23. pii: 6184142. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. VOGRIG A, Moritz CP, Camdessanche JP, Tholance Y, et al
    Unclear association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Mar 23. pii: 6181752. doi: 10.1093.
    PubMed    
    
    
    
16. BHARGAVA P, Kim S, Reyes AA, Grenningloh R, et al
    Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
    Brain. 2021 Mar 16. pii: 6173632. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. SABEL CE, Pearson JF, Mason DF, Willoughby E, et al
    The latitude gradient for multiple sclerosis prevalence is established in the early lifecourse.
    Brain. 2021 Mar 11. pii: 6168130. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. RAHMANZADEH R, Lu PJ, Barakovic M, Weigel M, et al
    Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
    Brain. 2021 Mar 9. pii: 6164965. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. MITSDORFFER M, Di Liberto G, Dotsch S, Sie C, et al
    Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity.
    Brain. 2021 Mar 9. pii: 6164962. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. XU Y, Smith KA, Hiyoshi A, Piehl F, et al
    Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis.
    Brain. 2021 Mar 9. pii: 6164964. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2021
21. KILPATRICK TJ, Binder MD
    Neuregulin therapy for multiple sclerosis: an each-way bet?
    Brain. 2021;144:6-8.
    PubMed    
    
    
    January 2021
22. DAL-BIANCO A, Grabner G, Kronnerwetter C, Weber M, et al
    Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.
    Brain. 2021 Jan 23. pii: 6114694. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. 
    Corrigendum to: Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2021 Jan 11. pii: 6082765. doi: 10.1093.
    PubMed    
    
    
    December 2020
24. KIM K, Probstel AK, Baumann R, Dyckow J, et al
    Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis.
    Brain. 2020 Dec 29. pii: 6055080. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. HALDER SK, Milner R
    Hypoxia in multiple sclerosis; is it the chicken or the egg?
    Brain. 2020 Dec 22. pii: 6044083. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. LUNN MP, Cornblath DR, Jacobs BC, Querol L, et al
    COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.
    Brain. 2020 Dec 14. pii: 6031904. doi: 10.1093.
    PubMed    
    
    
    
27. KEDDIE S, Pakpoor J, Mousele C, Pipis M, et al
    Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2020 Dec 14. pii: 6031905. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. KATARIA H, Hart CG, Alizadeh A, Cossoy M, et al
    Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032483. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. HOHLFELD R, Beltran E, Gerdes LA, Dornmair K, et al
    Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032479. doi: 10.1093.
    PubMed    
    
    
    
30. SMOLDERS J, Fransen NL, Huitinga I, Hamann J, et al
    Reply: Tissue-resident CD8+ memory T cells in multiple sclerosis.
    Brain. 2020 Dec 13. pii: 6032480. doi: 10.1093.
    PubMed    
    
    
    
31. EFTIMOV F, Lucke IM, Querol LA, Rajabally YA, et al
    Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2020;143:3214-3224.
    PubMed     Abstract available
    
    
    
32. PATERSON RW, Brown RL, Vivekanandam V, Foulkes AJM, et al
    Reply: Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e101.
    PubMed    
    
    
    
33. KARAPANAYIOTIDES T, Geka E, Prassopoulos P, Koutroulou I, et al
    Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?
    Brain. 2020;143:e100.
    PubMed    
    
    
    
34. CAO A, Rohaut B, Le Guennec L, Saheb S, et al
    Severe COVID-19-related encephalitis can respond to immunotherapy.
    Brain. 2020;143:e102.
    PubMed    
    
    
    November 2020
35. PETROU P, Kassis I, Levin N, Paul F, et al
    Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012789. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. PETZOLD A, Chua SYL, Khawaja AP, Keane PA, et al
    Retinal asymmetry in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 6012795. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. SCHIAVI S, Petracca M, Sun P, Fleysher L, et al
    Non-invasive quantification of inflammation, axonal and myelin injury in multiple sclerosis.
    Brain. 2020 Nov 30. pii: 5999115. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. STERIADE C, Titulaer MJ, Vezzani A, Sander JW, et al
    The association between systemic autoimmune disorders and epilepsy and its clinical implications.
    Brain. 2020 Nov 22. pii: 5998333. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. DE MEO E, Storelli L, Moiola L, Ghezzi A, et al
    In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology.
    Brain. 2020 Nov 21. pii: 5998271. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. MARIANO R, Messina S, Roca-Fernandez A, Leite MI, et al
    Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis.
    Brain. 2020 Nov 18. pii: 5989776. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. ELLENBERGER D, Flachenecker P, Fneish F, Frahm N, et al
    Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974108. doi: 10.1093.
    PubMed    
    
    
    
42. KALINCIK T, Malpas CB
    Reply: Aggressive multiple sclerosis - a matter of measurement and timing.
    Brain. 2020 Nov 11. pii: 5974107. doi: 10.1093.
    PubMed    
    
    
    October 2020
43. SUCKSDORFF M, Matilainen M, Tuisku J, Polvinen E, et al
    Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Brain. 2020 Oct 2. pii: 5917253. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. GAUDIOSO C, Naismith RT
    Optimizing treatment strategies in paediatric, adult and late-onset multiple sclerosis.
    Brain. 2020;143:2866-2868.
    PubMed    
    
    
    September 2020
45. AMATO MP, Fonderico M, Portaccio E, Pasto L, et al
    Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906150. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. OUELLETTE R, Treaba CA, Granberg T, Herranz E, et al
    7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis.
    Brain. 2020 Sep 16. pii: 5906152. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. WAGNON I, Helie P, Bardou I, Regnauld C, et al
    Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor.
    Brain. 2020 Sep 7. pii: 5902131. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. GERALDES R, Esiri MM, Perera R, Yee SA, et al
    Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships.
    Brain. 2020 Sep 2. pii: 5900415. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. ROOS I, Leray E, Frascoli F, Casey R, et al
    Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
    Brain. 2020;143:2742-2756.
    PubMed     Abstract available
    
    
    
50. KULLMANN DM
    Editorial.
    Brain. 2020;143:2625.
    PubMed    
    
    
    
51. RICHARD C, Ruiz A, Cavagna S, Bigotte M, et al
    Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination.
    Brain. 2020;143:2721-2732.
    PubMed     Abstract available
    
    
    
52. MANNARA F, Radosevic M, Planaguma J, Soto D, et al
    Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis.
    Brain. 2020;143:2709-2720.
    PubMed     Abstract available
    
    
    August 2020
53. BOUMAN PM, Steenwijk MD, Pouwels PJW, Schoonheim MM, et al
    Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis.
    Brain. 2020 Aug 21. pii: 5895168. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. CHITNIS T, Aaen G, Belman A, Benson L, et al
    Improved relapse recovery in paediatric compared to adult multiple sclerosis.
    Brain. 2020 Aug 18. pii: 5894047. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2020
55. SORENSEN PS, Sellebjerg F, Hartung HP, Montalban X, et al
    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Brain. 2020 Jul 24. pii: 5876125. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2020
56. JACKLE K, Zeis T, Schaeren-Wiemers N, Junker A, et al
    Molecular signature of slowly expanding lesions in progressive multiple sclerosis.
    Brain. 2020 Jun 24. pii: 5861738. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. KERBRAT A, Gros C, Badji A, Bannier E, et al
    Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.
    Brain. 2020 Jun 23. pii: 5861019. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. ZEKERIDOU A, Pittock SJ
    Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction.
    Brain. 2020;143:1622-1625.
    PubMed    
    
    
    May 2020
59. RAMBERGER M, Berretta A, Tan JMM, Sun B, et al
    Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.
    Brain. 2020 May 21. pii: 5841730. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. FRANSEN NL, Hsiao CC, van der Poel M, Engelenburg HJ, et al
    Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions.
    Brain. 2020 May 13. pii: 5836675. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. MALPAS CB, Manouchehrinia A, Sharmin S, Roos I, et al
    Early clinical markers of aggressive multiple sclerosis.
    Brain. 2020 May 9. pii: 5835340. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. KADOWAKI A, Quintana FJ
    The NLRP3 inflammasome in progressive multiple sclerosis.
    Brain. 2020;143:1286-1288.
    PubMed    
    
    
    
63. TAKAI Y, Misu T, Kaneko K, Chihara N, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Brain. 2020;143:1431-1446.
    PubMed     Abstract available
    
    
    April 2020
64. DIETRICH M, Koska V, Hecker C, Gottle P, et al
    Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
    Brain. 2020 Apr 15. pii: 5820386. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. MALHOTRA S, Costa C, Eixarch H, Keller CW, et al
    NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.
    Brain. 2020 Apr 13. pii: 5819591. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2020
66. KLEEREKOOPER I, Petzold A, Trip SA
    Anterior visual system imaging to investigate energy failure in multiple sclerosis.
    Brain. 2020 Mar 12. pii: 5804129. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2020
67. ROWE J
    Editorial.
    Brain. 2020;143:1.
    PubMed    
    
    
    November 2019
68. MEIJER KA, Steenwijk MD, Douw L, Schoonheim MM, et al
    Long-range connections are more severely damaged and relevant for cognition in multiple sclerosis.
    Brain. 2019 Nov 15. pii: 5626204. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2019
69. HAUSLER D, Torke S, Peelen E, Bertsch T, et al
    Reply: Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis.
    Brain. 2019 Oct 30. pii: 5610115. doi: 10.1093.
    PubMed    
    
    
    
70. SMOLDERS J, Damoiseaux J, Hupperts R
    Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis.
    Brain. 2019 Oct 30. pii: 5610116. doi: 10.1093.
    PubMed    
    
    
    
71. SABBAGH S, Almeida de Jesus A, Hwang S, Kuehn HS, et al
    Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
    Brain. 2019 Oct 11. pii: 5585662. doi: 10.1093.
    PubMed    
    
    
    
72. LANDON-CARDINAL O, Benveniste O, Allenbach Y
    Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
    Brain. 2019 Oct 11. pii: 5585663. doi: 10.1093.
    PubMed    
    
    
    
73. CRISP SJ, Dixon CL, Jacobson L, Chabrol E, et al
    Glycine receptor autoantibodies disrupt inhibitory neurotransmission.
    Brain. 2019 Oct 8. pii: 5583666. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. NUTMA E, Stephenson JA, Gorter RP, de Bruin J, et al
    A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Brain. 2019 Oct 3. pii: 5580333. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. KARAKAYA M, Wirth B
    Hereditary nodo-paranodopathies: genomic variants, not just autoantibodies, hit the protein.
    Brain. 2019;142:2895-2897.
    PubMed    
    
    
    September 2019
76. ELLIOTT C, Belachew S, Wolinsky JS, Hauser SL, et al
    Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Brain. 2019;142:2787-2799.
    PubMed     Abstract available
    
    
    
77. PENNER IK, Hartung HP
    The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis.
    Brain. 2019;142:2552-2555.
    PubMed    
    
    
    
78. BENVENISTE O, Allenbach Y
    Inclusion body myositis: accumulation of evidence for its autoimmune origin.
    Brain. 2019;142:2549-2551.
    PubMed    
    
    
    August 2019
79. MORQUETTE B, Juzwik CA, Drake SS, Charabati M, et al
    MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis.
    Brain. 2019 Aug 14. pii: 5549993. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. BROWNLEE WJ, Altmann DR, Prados F, Miszkiel KA, et al
    Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brain. 2019;142:2276-2287.
    PubMed     Abstract available
    
    
    July 2019
81. FEINSTEIN A, Meza C, Stefan C, Staines RW, et al
    Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis.
    Brain. 2019 Jul 30. pii: 5541023. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. WENTLING M, Lopez-Gomez C, Park HJ, Amatruda M, et al
    A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.
    Brain. 2019 Jul 15. pii: 5531715. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. HAUSLER D, Torke S, Peelen E, Bertsch T, et al
    High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.
    Brain. 2019 Jul 13. pii: 5532100. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. FITZGERALD KC, Kim K, Smith MD, Aston SA, et al
    Early complement genes are associated with visual system degeneration in multiple sclerosis.
    Brain. 2019 Jul 9. pii: 5530228. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. ROPELE S, Fazekas F
    Quantification of cortical damage in multiple sclerosis using DTI remains a challenge.
    Brain. 2019;142:1848-1850.
    PubMed    
    
    
    June 2019
86. FILIPPI M, Preziosa P, Banwell BL, Barkhof F, et al
    Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.
    Brain. 2019 Jun 17. pii: 5519813. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. PREZIOSA P, Kiljan S, Steenwijk MD, Meani A, et al
    Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex.
    Brain. 2019 Jun 5. pii: 5511700. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2019
88. MUNK NIELSEN N, Corn G, Frisch M, Stenager E, et al
    Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study.
    Brain. 2019 May 13. pii: 5488579. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. COTZOMI E, Stathopoulos P, Lee CS, Ritchie AM, et al
    Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
    Brain. 2019 May 5. pii: 5485817. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. GIOVANNONI G
    Survival: the ultimate long-term outcome in multiple sclerosis.
    Brain. 2019;142:1166-1167.
    PubMed    
    
    
    
91. PALACE J, Lin DY, Zeng D, Majed M, et al
    Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
    Brain. 2019;142:1310-1323.
    PubMed     Abstract available
    
    
    April 2019
92. VAN COEVORDEN-HAMEETE MH, de Bruijn MAAM, de Graaff E, Bastiaansen DAEM, et al
    The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.
    Brain. 2019 Apr 22. pii: 5476117. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. WEKERLE H
    Secondary progressive multiple sclerosis and the gut-brain axis.
    Brain. 2019;142:838-840.
    PubMed    
    
    
    March 2019
94. KINGWELL E, Leray E, Zhu F, Petkau J, et al
    Multiple sclerosis: effect of beta interferon treatment on survival.
    Brain. 2019 Mar 18. pii: 5382233. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. HOHLFELD R
    Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum.
    Brain. 2019;142:490-492.
    PubMed    
    
    
    February 2019
96. KADOWAKI A, Saga R, Lin Y, Sato W, et al
    Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis.
    Brain. 2019 Feb 15. pii: 5321131. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. MEXHITAJ I, Nyirenda MH, Li R, O'Mahony J, et al
    Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.
    Brain. 2019 Feb 12. pii: 5316384. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. ALLENBACH Y, Bolko L, Toquet S, Landon-Cardinal O, et al
    Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Brain. 2019 Feb 1. pii: 5305679. doi: 10.1093.
    PubMed    
    
    
    
99. PAPADOPOULOU C, Hong Y, Omoyinmi E, Brogan PA, et al
    Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Brain. 2019 Feb 1. pii: 5305681. doi: 10.1093.
    PubMed    
    
    
    January 2019
100. EDEN D, Gros C, Badji A, Dupont SM, et al
     Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
     Brain. 2019 Jan 30. pii: 5304670. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. NTRANOS A, Ntranos V, Bonnefil V, Liu J, et al
     Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis.
     Brain. 2019 Jan 28. pii: 5303708. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. CHEN Y, Podojil JR, Kunjamma RB, Jones J, et al
     Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis.
     Brain. 2019 Jan 17. pii: 5289373. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2018
103. VON ESSEN MR, Ammitzboll C, Hansen RH, Petersen ERS, et al
     Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.
     Brain. 2018 Dec 17. pii: 5250831. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. KAUNZNER UW, Kang Y, Zhang S, Morris E, et al
     Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
     Brain. 2018 Dec 15. pii: 5250435. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2018
105. ZALC B
     One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease.
     Brain. 2018 Nov 20. pii: 5194497. doi: 10.1093.
     PubMed    
     
     
     
106. ALY L, Korn T
     Multiple sclerosis: is it all black and white in optical coherence tomography?
     Brain. 2018;141:3088-3091.
     PubMed    
     
     
     
107. DEBANNE D, El Far O
     Pre- and postsynaptic effects of LGI1 autoantibodies in a murine model of limbic encephalitis.
     Brain. 2018;141:3092-3095.
     PubMed    
     
     
     
108. AESCHLIMANN FA, Fremond ML, Duffy D, Rice GI, et al
     A child with severe juvenile dermatomyositis treated with ruxolitinib.
     Brain. 2018;141:e80.
     PubMed    
     
     
     
109. ALLENBACH Y, Toquet S, Landon-Cardinal O, Benveniste O, et al
     Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib.
     Brain. 2018;141:e81.
     PubMed    
     
     
     October 2018
110. CALDITO NG, Saidha S, Sotirchos ES, Dewey BE, et al
     Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.
     Brain. 2018 Oct 11. pii: 5127751. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. DOETS AY, Verboon C, van den Berg B, Harbo T, et al
     Regional variation of Guillain-Barre syndrome.
     Brain. 2018;141:2866-2877.
     PubMed     Abstract available
     
     
     September 2018
112. BAKER D, Pryce G, Amor S, Giovannoni G, et al
     Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis.
     Brain. 2018 Sep 12. pii: 5095715. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. EIJLERS AJC, van Geest Q, Dekker I, Steenwijk MD, et al
     Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
     Brain. 2018;141:2605-2618.
     PubMed     Abstract available
     
     
     June 2018
114. MACHADO-SANTOS J, Saji E, Troscher AR, Paunovic M, et al
     The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.
     Brain. 2018 Jun 4. pii: 5032773. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. STANKOFF B, Louapre C
     Can we use regional grey matter atrophy sequence to stage neurodegeneration in multiple sclerosis?
     Brain. 2018;141:1580-1583.
     PubMed    
     
     
     May 2018
116. CAMARA-LEMARROY CR, Metz L, Meddings JB, Sharkey KA, et al
     The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.
     Brain. 2018 May 30. pii: 5025744. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. BARRO C, Benkert P, Disanto G, Tsagkas C, et al
     Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
     Brain. 2018 May 30. pii: 5025690. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. ESHAGHI A, Marinescu RV, Young AL, Firth NC, et al
     Progression of regional grey matter atrophy in multiple sclerosis.
     Brain. 2018 May 8. pii: 4993898. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. LADISLAU L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, et al
     JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
     Brain. 2018 May 8. pii: 4993951. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2018
120. CONRAD BN, Barry RL, Rogers BP, Maki S, et al
     Multiple sclerosis lesions affect intrinsic functional connectivity of the spinal cord.
     Brain. 2018 Apr 10. pii: 4965865. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. VAN LANGELAAR J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, et al
     T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
     Brain. 2018 Apr 5. pii: 4961484. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2018
122. STEYERBERG EW, Claggett B
     Towards personalized therapy for multiple sclerosis: limitations of observational data.
     Brain. 2018 Mar 3. pii: 4919652. doi: 10.1093.
     PubMed    
     
     
     
123. KALINCIK T
     Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data.
     Brain. 2018 Mar 3. pii: 4919653. doi: 10.1093.
     PubMed    
     
     
     
124. STEPHENSON EL, Mishra MK, Moussienko D, Laflamme N, et al
     Chondroitin sulfate proteoglycans as novel drivers of leucocyte infiltration in multiple sclerosis.
     Brain. 2018 Mar 1. pii: 4915907. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2018
125. ARRAMBIDE G, Tintore M, Espejo C, Auger C, et al
     The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.
     Brain. 2018 Feb 16. pii: 4866204. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2018
126. SMETS I, Fiddes B, Garcia-Perez JE, He D, et al
     Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.
     Brain. 2018 Jan 18. pii: 4817414. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2017
127. KIM RY, Mangu D, Hoffman AS, Kovash R, et al
     Oestrogen receptor beta ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis.
     Brain. 2017 Dec 8. pii: 4710057. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2017
128. GRANBERG T, Fan Q, Treaba CA, Ouellette R, et al
     In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis.
     Brain. 2017 Oct 10. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2017
129. ROCCA MA, Sormani MP, Rovaris M, Caputo D, et al
     Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.
     Brain. 2017 Sep 27. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. DATTA G, Colasanti A, Rabiner EA, Gunn RN, et al
     Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
     Brain. 2017 Sep 23. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. KALINCIK T, Manouchehrinia A, Sobisek L, Jokubaitis V, et al
     Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
     Brain. 2017;140:2426-2443.
     PubMed     Abstract available
     
     
     July 2017
132. SCOLDING NJ, Pasquini M, Reingold SC, Cohen JA, et al
     Cell-based therapeutic strategies for multiple sclerosis.
     Brain. 2017 Jul 21. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2017
133. DELMONT E, Manso C, Querol L, Cortese A, et al
     Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.
     Brain. 2017 May 28. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. ZRZAVY T, Hametner S, Wimmer I, Butovsky O, et al
     Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.
     Brain. 2017 May 24. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. HACOHEN Y, Ciccarelli O, Hemingway C
     Abnormal white matter development in children with multiple sclerosis and monophasic acquired demyelination.
     Brain. 2017;140:1172-1174.
     PubMed    
     
     
     April 2017
136. EL BEHI M, Sanson C, Bachelin C, Guillot-Noel L, et al
     Adaptive human immunity drives remyelination in a mouse model of demyelination.
     Brain. 2017;140:967-980.
     PubMed     Abstract available
     
     
     March 2017
137. LONGONI G, Brown RA, MomayyezSiahkal P, Elliott C, et al
     White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.
     Brain. 2017 Mar 14. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. JURYNCZYK M, Geraldes R, Probert F, Woodhall MR, et al
     Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
     Brain. 2017;140:617-627.
     PubMed     Abstract available
     
     
     February 2017
139. PONATH G, Ramanan S, Mubarak M, Housley W, et al
     Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology.
     Brain. 2017;140.
     PubMed     Abstract available
     
     
     June 2016
140. ARAUJO AQ, Silva MT, Araujo AP
     Zika virus-associated neurological disorders: a review.
     Brain. 2016.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: